Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AAVantgarde Bio logo — Delivering the next generation gene therapies

AAVantgarde Bio

Delivering the next generation gene therapies

Founded 2021 Italy Italy 19 employees Series A Total: $61.00M Biotechnology, Health Care

General Information

Company Name AAVantgarde Bio
Founded Year 2021
Location Italy Italy
Employees 19
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when AAVantgarde Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AAVantgarde Bio

AAVantgarde Bio is a biotechnology startup based in Italy, with the slogan "Delivering the next generation gene therapies." Established in 2021, the company focuses on developing gene therapies targeting inherited retinal disorders. The startup recently received a significant €61.00M Series A investment on June 6, 2023, with the backing of prominent investors including Atlas Venture, Longwood Fund, Sofinnova Partners, Forbion, and Fondazione Telethon. AAVantgarde Bio has emerged from research conducted at the Telethon Institute of Genetics and Medicine and has the support of Sofinnova Partners, showcasing its promising trajectory in the biotech industry.

Taxonomy: biotech, gene therapy, startup, biomedical research, inherited retinal disorders, AAV-based gene therapies, genetic medicine, Sofinnova Partners, Telethon Institute of Genetics and Medicine, innovation, cutting-edge, biomedical startup, innovative therapies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 5
Investor Investor Investor Investor
•••• •••• 		06 Jun 2023
Seed Round •••••• 1
Investor
30 Jun 2021

AAVantgarde Bio Alternatives & Competitors

AAVantgarde Bio vs
Chimeron Bio
Chimeron Bio United States

Redefining genetic medicine with future-forward RNA technology designed to deliver meaningful patien...

Angel
12 employees
Biotechnology, Health Care
AAVantgarde Bio vs
SonoThera
SonoThera United States

SonoThera is developing ultrasound-mediated nonviral genetic therapies.

Series A
54 employees
Biopharma, Biotechnology
AAVantgarde Bio vs
Function
Function United States

Personalized functional genomics transforming the future of cancer

Series A
7 employees
Biotechnology, Health and Wellness

FAQ About AAVantgarde Bio

Delivering the next generation gene therapies
AAVantgarde Bio was founded in 2021.
AAVantgarde Bio is headquartered in Italy.
AAVantgarde Bio operates in the following industries: Biotechnology, Health Care.
AAVantgarde Bio has approximately 19 employees.
AAVantgarde Bio has completed 2 funding rounds, raising a total of $61.00M. The latest funding stage is Series A.
Top alternatives and competitors to AAVantgarde Bio include Chimeron Bio, SonoThera, Function, GenEditBio Limited, Geneus Tech Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AAVantgarde Bio and Chimeron Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AAVantgarde Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy